Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study
Authors:
Open Access
- 9 July 2020
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 37 (9) , 3775-3790
Abstract
Introduction The phase 3 InforMing the PAthway of COPD (chronic obstructive pulmonary disease) Treatment (IMPACT) trial, single-inhaler therapy with fluticasone furoate (FF) 100 μg, umeclidinium (UMEC) 62.5 μg, and vilanterol (VI) 25 μg demonstrated a reduction in the rate of moderate or severe exacerbations compared with FF/VI or UMEC/VI in patients with symptomatic COPD at risk of exacerbations. This article reports additional evidence of improvements in symptoms and health-related quality of life (HRQoL) with FF/UMEC/VI compared with either FF/VI or UMEC/VI from the IMPACT study. Methods Patient-reported HRQoL assessments and symptom measures included as pre-specified IMPACT end points were the St George's Respiratory Questionnaire (SGRQ), COPD Assessment Test (CAT), and Baseline Dyspnea Index (BDI) as the anchor for the Transitional Dyspnea Index (TDI) focal score (BDI/TDI) in a subset of patients enrolled at study sites in North America and Europe. Change from baseline was assessed at weeks 4, 28, and 52. Results The intent-to-treat population included 10,355 patients (TDI population: 5058 patients). Clinically meaningful improvements in SGRQ total score between baseline and week 52 favored FF/UMEC/VI over FF/VI (− 1.8 units, p < 0.001) and UMEC/VI (− 1.8 units, p < 0.001). Similar improvements in the CAT and TDI focal score were also observed with FF/UMEC/VI versus FF/VI or UMEC/VI. Conclusions This study demonstrates that in patients with symptomatic COPD at risk of exacerbations, once-daily FF/UMEC/VI, compared with FF/VI or UMEC/VI, improves patient-perceived HRQoL and symptoms. Trial Registration Number NCT02164513.Keywords
Funding Information
- GlaxoSmithKline (clinicaltrials.gov ID: NCT02164513)
This publication has 23 references indexed in Scilit:
- Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPDNew England Journal of Medicine, 2016
- Effect of tiotropium on night-time awakening and daily rescue medication use in patients with COPDRespiratory Research, 2016
- Strategies to improve anxiety and depression in patients with COPD: a mental health perspectiveNeuropsychiatric Disease and Treatment, 2016
- Minimum clinically important difference for the COPD Assessment Test: a prospective analysisThe Lancet Respiratory Medicine, 2014
- Minimal Clinically Important Differences in Pharmacological TrialsAmerican Journal of Respiratory and Critical Care Medicine, 2014
- Sleep disorders in COPD: the forgotten dimensionEuropean Respiratory Review, 2013
- Beyond FEV1 in COPD: a review of patient-reported outcomes and their measurementInternational Journal of Chronic Obstructive Pulmonary Disease, 2012
- Development and first validation of the COPD Assessment TestEuropean Respiratory Journal, 2009
- Improving the process and outcome of care in COPD: development of a standardised assessment toolPrimary Care Respiratory Journal, 2009
- Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory QuestionnaireChest, 2007